Small Cell Lung Cancer

Click on the tabs above by lung cancer type to view active trials.
Protocol #SponsorProtocol Title
NCT02296125

AstraZeneca
D5160C00007, 2014-002694-11, U1111-1160-2242
A Phase III, Double-blind, Randomized Study to Assess the Safety and Efficacy of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer
NCT02367781
Hoffmann-La Roche
GO29537, 2014-003206-32
A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
NCT02367794

Hoffmann-La Roche
GO29437
A Phase III, Open-label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of MPDL3208A (Anti-PDL-1 Antibody) in Combination with Carboplatin + Paclitaxel or MPDL3208A in Combination with Carboplatin + Nab-paclitaxel Versus Carboplatin + Nab-paclitaxel in Chemotherapy-naive Patients with Stage IV Squamous Non-small Cell Lung Cancer
NCT02125461


AstraZeneca
D4191C00001
A Phase III Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients with Stage III Unresectable Non-Small Cell Lung Cancer
NCT02477826Bristol-Myers Squibb
CA209-227, 2014-003630-23
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, Versus Platinum Doublet Chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Non-small cell lung cancers (NSCLC) are divided by histology (squamous and non-squamous non-small cell cancers) and by molecular markers to select treatment.

Pemetrexed in combination with platin-chemotherapy has been demonstrated to be superior to gemcitabine-platin chemotherapy in non-squamous NSCLC. Anti-angiogenic therapy with bevacizumab has demonstrated survival benefit when added to paclitaxel-carboplatin chemotherapy in non-squamous NSCLC. Small molecule inhibitors of the Epidermal Growth Factor Receptor (EGFR) have been demonstrated to improve survival in patients with NSCLC previously treated with chemotherapy, and have even been established as superior to chemotherapy in first-line treatment of NSCLC harboring activating mutations of EGFR.

NGOC cancer doctors are offering participation in several clinical trials evaluating these agents and pathways. We are increasingly able to offer individualized, personalized approaches based on individual tumor characteristics.

Protocol #SponsorProtocol Title
NCT0220757


CytRxA Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy
Non-small cell lung cancers (NSCLC) are divided by histology (squamous and non-squamous non-small cell cancers) and by molecular markers to select treatment.

Pemetrexed in combination with platin-chemotherapy has been demonstrated to be superior to gemcitabine-platin chemotherapy in non-squamous NSCLC. Anti-angiogenic therapy with bevacizumab has demonstrated survival benefit when added to paclitaxel-carboplatin chemotherapy in non-squamous NSCLC. Small molecule inhibitors of the Epidermal Growth Factor Receptor (EGFR) have been demonstrated to improve survival in patients with NSCLC previously treated with chemotherapy, and have even been established as superior to chemotherapy in first-line treatment of NSCLC harboring activating mutations of EGFR.

NGOC cancer doctors are offering participation in several clinical trials evaluating these agents and pathways. We are increasingly able to offer individualized, personalized approaches based on individual tumor characteristics.